CNTA Stock Forecast 2025-2026
Distance to CNTA Price Targets
CNTA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Centessa (CNTA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CNTA and similar high-potential opportunities.
Latest CNTA Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, CNTA has a bullish consensus with a median price target of $30.50 (ranging from $26.00 to $38.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $12.30, the median forecast implies a 148.1% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Biren Amin at Piper Sandler, projecting a 209.1% upside. Conversely, the most conservative target is provided by Jeffrey Hung at Morgan Stanley, suggesting a 111.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNTA Analyst Ratings
CNTA Price Target Range
Latest CNTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | Piper Sandler | Biren Amin | Overweight | Initiates | $38.00 |
| Mar 26, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $28.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $27.00 |
| Feb 10, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $0.00 |
| Jan 7, 2025 | TD Cowen | Stacy Ku | Buy | Initiates | $0.00 |
| Nov 15, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $28.00 |
| Sep 19, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $33.00 |
| Sep 19, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Upgrade | $26.00 |
| Sep 16, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $35.00 |
| Sep 11, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $24.00 |
| Sep 11, 2024 | Jefferies | Kelly Shi | Buy | Maintains | $19.00 |
| Sep 9, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $20.00 |
| Aug 14, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $14.00 |
| Jul 18, 2024 | Oppenheimer | Francois Brisebois | Outperform | Initiates | $14.00 |
| Jun 21, 2024 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $11.00 |
| Apr 1, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $15.00 |
| Nov 15, 2023 | Jefferies | Kelly Shi | Buy | Upgrade | $11.00 |
| Oct 26, 2023 | Morgan Stanley | Matthew Harrison | Equal-Weight | Upgrade | $8.00 |
| Aug 15, 2023 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $10.00 |
| Aug 15, 2023 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $5.00 |
Centessa Pharmaceuticals plc - ADR (CNTA) Competitors
The following stocks are similar to Centessa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Centessa Pharmaceuticals plc - ADR (CNTA) Financial Data
Centessa Pharmaceuticals plc - ADR has a market capitalization of $1.64B with a P/E ratio of -6.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -73.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Centessa Pharmaceuticals plc - ADR (CNTA) Business Model
About Centessa Pharmaceuticals plc - ADR
Develops innovative medicines in biotechnology.
Centessa Pharmaceuticals aggregates high-potential biopharmaceutical programs across various therapeutic areas, including oncology, rare diseases, and immunology. The company streamlines operations to accelerate the development of its therapeutic candidates, generating revenue through advancements in drug development and potential commercialization.
As an American Depositary Receipt (ADR), Centessa Pharmaceuticals provides U.S. investors easier access to invest in foreign biopharmaceutical innovations. This structure enhances its market visibility and broadens its investor base, which is essential for securing funding for advanced research and development projects.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
77
CEO
Dr. Saurabh Saha M.D., Ph.D.
Country
United Kingdom
IPO Year
2021
Website
centessa.comCentessa Pharmaceuticals plc - ADR (CNTA) Latest News & Analysis
Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q4 and full-year financial results for 2024 on March 24, 2025, detailing recent business highlights.
Centessa Pharmaceuticals' quarterly and annual financial results provide insight into its performance and growth potential, influencing stock valuation and investor sentiment.
Centessa Pharmaceuticals will present Phase 1 trial data for ORX750, an OX2R agonist for narcolepsy and hypersomnia, at the AAN Annual Meeting on April 5-9, 2025. Phase 2a trial ongoing.
The announcement of ORX750's clinical trial data presentation may boost Centessa Pharmaceuticals' stock, highlighting potential advancements in treating narcolepsy and attracting investor interest.
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
3 months agoCentessa Pharmaceuticals appointed Dr. Stephen Kanes as Chief Medical Officer. He brings over 30 years of experience in neuroscience and drug development.
The appointment of a highly experienced CMO like Dr. Kanes can enhance Centessa's drug development capabilities, potentially increasing investor confidence and impacting stock performance.
Centessa Pharmaceuticals has discontinued its SerpinPC candidate for Hemophilia B, saving $200 million. Positive results from phase 1 and ongoing phase 2a studies of ORX750 are anticipated in 2025.
Centessa's decision to abandon SerpinPC frees up $200 million, enhancing financial stability. Positive data from ORX750 bolsters prospects for future growth in sleep disorder treatments.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
5 months agoCentessa Pharmaceuticals (Nasdaq: CNTA) reported its Q3 2024 financial results and provided a business update on November 12, 2024.
Centessa Pharmaceuticals' Q3 financial results and business update signal its progress in drug development, impacting investor sentiment and potential stock performance.
Centessa Pharmaceuticals (NASDAQ: CNTA) has nearly doubled in value this year, with Morgan Stanley significantly raising its price target, indicating potential further growth.
Centessa Pharmaceuticals' stock surge and Morgan Stanley's increased price target signal strong growth potential, attracting investor interest and indicating bullish sentiment for the biotech sector.
Frequently Asked Questions About CNTA Stock
What is Centessa Pharmaceuticals plc - ADR's (CNTA) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Centessa Pharmaceuticals plc - ADR (CNTA) has a median price target of $30.50. The highest price target is $38.00 and the lowest is $26.00.
Is CNTA stock a good investment in 2025?
According to current analyst ratings, CNTA has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNTA stock?
Wall Street analysts predict CNTA stock could reach $30.50 in the next 12 months. This represents a 148.1% increase from the current price of $12.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Centessa Pharmaceuticals plc - ADR's business model?
Centessa Pharmaceuticals aggregates high-potential biopharmaceutical programs across various therapeutic areas, including oncology, rare diseases, and immunology. The company streamlines operations to accelerate the development of its therapeutic candidates, generating revenue through advancements in drug development and potential commercialization.
What is the highest forecasted price for CNTA Centessa Pharmaceuticals plc - ADR?
The highest price target for CNTA is $38.00 from Biren Amin at Piper Sandler, which represents a 209.1% increase from the current price of $12.30.
What is the lowest forecasted price for CNTA Centessa Pharmaceuticals plc - ADR?
The lowest price target for CNTA is $26.00 from Jeffrey Hung at Morgan Stanley, which represents a 111.5% increase from the current price of $12.30.
What is the overall CNTA consensus from analysts for Centessa Pharmaceuticals plc - ADR?
The overall analyst consensus for CNTA is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.50.
How accurate are CNTA stock price projections?
Stock price projections, including those for Centessa Pharmaceuticals plc - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.